Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Melanoma: NCT06540391 Clinical Landscape Report 2026
16 October 2026
NCT06540391 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nadofaragene firadenovec-vncg in Non-Muscle Invasive Bladder Neoplasms: NCT06545955 Clinical Landscape Report 2026
16 October 2026
NCT06545955 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Alpelisib in Melanoma, Cutaneous Malignant: NCT06545682 Clinical Landscape Report 2026
16 October 2026
NCT06545682 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYNCAR-001+STK-009(Synthekine) in Scleroderma, Diffuse: NCT06544330 Clinical Landscape Report 2026
16 October 2026
NCT06544330 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RD-06-04 in Idiopathic Inflammatory Myopathies: NCT06549296 Clinical Landscape Report 2026
16 October 2026
NCT06549296 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Pemigatinib in Lung Cancer: NCT06551896 Clinical Landscape Report 2026
16 October 2026
NCT06551896 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Endometrial Carcinoma: NCT06548763 Clinical Landscape Report 2026
16 October 2026
NCT06548763 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Medroxyprogesterone Acetate in Mismatch repair-deficient Endometrial Carcinoma: NCT06549855 Clinical Landscape Report 2026
16 October 2026
NCT06549855 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Bulumtatug fuvedotin in Non-Muscle Invasive Bladder Neoplasms: NCT06551233 Clinical Landscape Report 2026
16 October 2026
NCT06551233 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Temozolomide in Locally Advanced Melanoma: NCT06553781 Clinical Landscape Report 2026
16 October 2026
NCT06553781 clinical landscape for Locally Advanced Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab biosimilar(Formycon) in Melanoma: NCT06551064 Clinical Landscape Report 2026
16 October 2026
NCT06551064 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KD01 in Endometrial Carcinoma: NCT06552598 Clinical Landscape Report 2026
16 October 2026
NCT06552598 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.